Last 7 days
-2.6%
Last 90 days
-15.9%
Trailing 12 Months
-79.2%
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 12.3M | 13.7M | 6.4M | 0 |
2022 | 2.7M | 2.7M | 11.5M | 10.8M |
2021 | 8.3M | 8.2M | 7.6M | 2.8M |
2020 | 2.6M | 3.5M | 3.6M | 8.9M |
2019 | 31.8M | 7.5M | 6.3M | 4.1M |
2018 | 39.3M | 36.4M | 33.4M | 30.5M |
2017 | 37.6M | 51.8M | 41.9M | 42.2M |
2016 | 43.5M | 44.4M | 32.8M | 35.4M |
2015 | 13.3M | 14.8M | 37.1M | 40.6M |
2014 | 14.4M | 17.4M | 9.7M | 10.5M |
2013 | 3.9M | 4.2M | 12.9M | 13.5M |
2012 | 8.4M | 6.4M | 4.6M | 4.1M |
2011 | 7.9M | 9.2M | 10.5M | 9.8M |
2010 | 8.4M | 7.6M | 6.9M | 6.1M |
2009 | 0 | 0 | 0 | 9.1M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jun 30, 2023 | sumner michael john | acquired | - | - | 35,000 | chief medical officer |
Jun 05, 2023 | zoth lota s. | sold | -3,192 | 0.56 | -5,700 | - |
May 16, 2023 | benito simon x | acquired | - | - | 19,000 | - |
May 16, 2023 | yarno wendy l | acquired | - | - | 19,000 | - |
May 16, 2023 | zoth lota s. | acquired | - | - | 19,000 | - |
May 16, 2023 | miller ann calby | acquired | - | - | 19,000 | - |
May 16, 2023 | shepard jay | acquired | - | - | 19,000 | - |
May 16, 2023 | weiner david b. | acquired | - | - | 19,000 | - |
May 16, 2023 | dansey roger d | acquired | - | - | 19,000 | - |
May 13, 2023 | dansey roger d | acquired | - | - | 12,000 | - |
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Dec 06, 2023 | CITIGROUP INC | reduced | -29.27 | -833 | 1,338 | -% |
Nov 17, 2023 | JACOBS LEVY EQUITY MANAGEMENT, INC | reduced | -46.45 | -511,438 | 447,340 | -% |
Nov 16, 2023 | Creative Planning | reduced | -19.9 | -2,422 | 5,596 | -% |
Nov 16, 2023 | Financial Gravity Asset Management, Inc. | added | - | -10.00 | 7.00 | -% |
Nov 15, 2023 | GSA CAPITAL PARTNERS LLP | new | - | 116,000 | 116,000 | 0.01% |
Nov 15, 2023 | GTS SECURITIES LLC | new | - | 5,728 | 5,728 | -% |
Nov 15, 2023 | Tudor Investment Corp Et Al | reduced | -59.16 | -159,209 | 87,922 | -% |
Nov 15, 2023 | Virtu Financial LLC | sold off | -100 | -21,000 | - | -% |
Nov 15, 2023 | MORGAN STANLEY | reduced | -19.23 | -49,837 | 118,349 | -% |
Nov 15, 2023 | OLD MISSION CAPITAL LLC | sold off | -100 | -47,296 | - | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Jul 10, 2023 | state street corp | 0.33% | 877,447 | SC 13G/A | |
Jul 07, 2023 | blackrock inc. | 2.3% | 6,086,623 | SC 13G/A | |
Feb 09, 2023 | state street corp | 12.61% | 31,472,352 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 6.83% | 17,042,500 | SC 13G/A | |
Jan 24, 2023 | blackrock inc. | 9.3% | 23,284,119 | SC 13G/A | |
Apr 11, 2022 | state street corp | 10.49% | 23,267,928 | SC 13G/A | |
Feb 11, 2022 | state street corp | 6.32% | 13,300,430 | SC 13G/A | |
Feb 01, 2022 | blackrock inc. | 8.7% | 18,244,914 | SC 13G/A | |
Feb 11, 2021 | wasatch advisors inc | - | 0 | SC 13G/A | |
Feb 11, 2021 | nikko asset management americas, inc. | 0% | 0 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Nov 28, 2023 | DEF 14A | DEF 14A | |
Nov 17, 2023 | PRE 14A | PRE 14A | |
Nov 09, 2023 | S-3 | S-3 | |
Nov 09, 2023 | 8-K | Current Report | |
Nov 09, 2023 | 10-Q | Quarterly Report | |
Nov 02, 2023 | 8-K | Current Report | |
Oct 10, 2023 | 8-K | Current Report |
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
HILS | 30.9B | - | 5.25% | 401813.88% | -3.6K | 218.4K | - | -102.45% |
MRNA | 30.5B | 10.7B | 8.54% | -55.34% | -8.79 | 2.86 | -53.67% | -129.46% |
ALNY | 22.2B | 1.7B | 4.15% | -23.37% | -43.62 | 12.9 | 79.37% | 56.87% |
BMRN | 17.9B | 2.3B | 11.05% | -8.44% | 121.62 | 7.74 | 15.05% | 75.21% |
INCY | 12.4B | 3.6B | 0.84% | -34.33% | 29.1 | 3.43 | 8.35% | -51.49% |
MID-CAP | ||||||||
APLS | 7.6B | 272.9M | 35.37% | 34.74% | -12.51 | 27.78 | 141.38% | 4.43% |
BBIO | 5.9B | - | 14.36% | 263.35% | -10.02 | 48.33 | 54.84% | -12.96% |
ACAD | 3.6B | 631.9M | -7.32% | 48.57% | -24.01 | 5.65 | 23.54% | 31.53% |
AXSM | 3.3B | 223.4M | 11.28% | -10.13% | -16.47 | 14.87 | - | -26.24% |
ARWR | 2.6B | 240.7M | -10.83% | -25.35% | -12.82 | 10.93 | -1.03% | -16.59% |
SMALL-CAP | ||||||||
CPRX | 1.5B | 348.4M | 11.36% | -14.92% | 24.59 | 4.38 | 81.69% | -7.29% |
NVAX | 656.6M | 1.0B | -22.00% | -67.89% | -1.2 | 0.63 | -43.15% | 58.48% |
INO | 100.5M | 6.4M | - | -79.23% | -0.61 | 15.6 | -44.11% | 50.48% |
IBIO | 39.5M | - | 376.67% | 112.17% | -0.61 | - | - | -29.23% |
CRBP | 23.3M | - | 25.24% | 3980.68% | -0.49 | - | - | -13.74% |
Income Statement (Quarterly) | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Revenue | -10.6% | 1,938,745 | 2,168,233 | 2,207,171 | 124,666 | 9,154,133 | 857,667 | 669,814 | 839,115 | 291,698 | 928,111 | 769,237 | 5,580,581 | 896,710 | 1,067,399 | 1,327,274 | 279,488 | 866,863 | 135,674 | 2,829,905 | 2,502,624 | 2,000,868 |
Operating Expenses | -3.6% | 35,941,458 | 37,267,068 | 44,067,121 | 56,070,821 | 44,911,177 | 104,921,721 | 71,932,069 | 106,347,454 | 60,244,852 | 83,474,759 | 52,925,612 | 34,920,019 | 36,565,618 | 33,448,085 | 26,559,542 | 30,700,541 | 24,818,650 | 28,336,367 | 31,364,917 | 32,001,788 | 28,643,551 |
S&GA Expenses | -26.6% | 9,925,055 | 13,523,098 | 13,890,610 | 13,950,944 | 11,824,047 | 48,456,836 | 15,953,458 | 14,048,635 | 13,156,183 | 12,666,341 | 13,881,194 | 8,617,458 | 10,110,506 | 11,071,510 | 7,448,354 | 8,696,586 | 5,681,441 | 5,850,101 | 6,975,029 | 5,636,141 | 6,791,693 |
R&D Expenses | -34.7% | 15,503,032 | 23,743,970 | 30,176,511 | 42,119,877 | 33,087,130 | 56,464,885 | 55,978,611 | 92,298,819 | 47,088,669 | 70,808,418 | 39,044,418 | 26,302,561 | 26,455,112 | 22,376,575 | 19,111,188 | 22,003,955 | 19,137,209 | 22,486,266 | 24,389,888 | 26,365,647 | 21,851,858 |
EBITDA Margin | 100.0% | - | -12.01 | -19.17 | -26.57 | -28.21 | -216 | -191 | -168 | -26.53 | -16.00 | -22.40 | -17.38 | -47.16 | -59.99 | -12.46 | -7.66 | - | - | - | - | - |
Interest Expenses | 0% | 313,488 | 313,488 | 313,488 | 313,488 | 313,488 | 313,488 | 313,488 | 480,313 | 476,374 | 466,726 | 513,034 | 1,068,008 | 1,984,046 | 2,846,641 | 2,803,755 | 2,668,837 | 2,428,671 | 2,194,783 | 656,248 | -156,261 | - |
Income Taxes | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -87,764 | - | -106,771 | -62,800 | - | - |
Earnings Before Taxes | 4.5% | -33,929,864 | -35,534,533 | -40,649,317 | -54,463,139 | -37,783,896 | -108,497,311 | -76,908,506 | -106,947,580 | -60,169,041 | -82,139,958 | -53,967,744 | -22,415,201 | 20,931,010 | -128,270,709 | -33,135,404 | -38,235,146 | -23,536,452 | -29,685,847 | -29,351,667 | -32,962,205 | -25,015,672 |
EBT Margin | 100.0% | - | -12.34 | -19.56 | -27.06 | -28.66 | -219 | -194 | -170 | -27.19 | -16.83 | -23.21 | -18.36 | -50.05 | -63.03 | -13.56 | -8.14 | - | - | - | - | - |
Net Income | 4.6% | -33,900,000 | -35,534,533 | -40,649,317 | -54,463,139 | -37,783,896 | -108,497,311 | -79,073,719 | -106,947,580 | -60,169,041 | -82,139,958 | -54,402,131 | -24,338,380 | 19,171,336 | -129,172,466 | -33,135,404 | -37,662,038 | -23,090,693 | -29,387,226 | -29,219,262 | -32,962,205 | -25,015,672 |
Net Income Margin | 100.0% | - | -12.34 | -19.55 | -27.26 | -28.84 | -221 | -196 | -171 | -27.48 | -17.33 | -23.78 | -18.76 | -50.33 | -62.69 | -13.35 | -8.04 | - | - | - | - | - |
Free Cashflow | 100.0% | - | -32,338,571 | -36,961,461 | -36,505,141 | -67,552,146 | -51,245,185 | -61,882,102 | -38,534,821 | -46,659,317 | -78,667,141 | -53,078,252 | -52,178,566 | -74,540,403 | -27,187,069 | -25,593,673 | -13,851,789 | - | - | - | - | - |
Balance Sheet | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Assets | -17.1% | 193 | 233 | 267 | 349 | 392 | 459 | 446 | 496 | 536 | 592 | 655 | 540 | 438 | 443 | 339 | 144 | 152 | 165 | 191 | 131 | 141 |
Current Assets | -14.0% | 175 | 203 | 234 | 315 | 350 | 416 | 400 | 448 | 487 | 542 | 588 | 471 | 377 | 382 | 276 | 94.00 | 99.00 | 111 | 135 | 88.00 | 94.00 |
Cash Equivalents | -64.3% | 19.00 | 53.00 | 28.00 | 46.00 | 22.00 | 41.00 | 59.00 | 71.00 | 68.00 | 59.00 | 84.00 | 251 | 179 | 215 | 158 | 22.00 | 16.00 | 20.00 | 21.00 | 24.00 | 19.00 |
Net PPE | -10.7% | 6.00 | 6.00 | 7.00 | 8.00 | 16.00 | 16.00 | 17.00 | 17.00 | 18.00 | 18.00 | 11.00 | 11.00 | 11.00 | 11.00 | 12.00 | 13.00 | 14.00 | 14.00 | 15.00 | 16.00 | 16.00 |
Goodwill | -100.0% | - | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 |
Liabilities | -13.7% | 55.00 | 64.00 | 67.00 | 126 | 125 | 162 | 90.00 | 96.00 | 82.00 | 83.00 | 73.00 | 79.00 | 114 | 257 | 151 | 139 | 115 | 109 | 110 | 44.00 | 37.00 |
Current Liabilities | -15.8% | 44.00 | 52.00 | 55.00 | 97.00 | 95.00 | 131 | 59.00 | 66.00 | 51.00 | 52.00 | 42.00 | 42.00 | 41.00 | 38.00 | 32.00 | 32.00 | 20.00 | 24.00 | 27.00 | 35.00 | 28.00 |
Shareholder's Equity | -18.4% | 138 | 169 | 199 | 222 | 267 | 298 | 355 | 400 | 454 | 509 | 582 | 461 | 324 | 186 | 188 | 5.00 | 36.00 | 56.00 | 81.00 | 87.00 | 104 |
Retained Earnings | -2.2% | -1,597 | -1,564 | -1,500 | -1,487 | -1,433 | -1,400 | -1,300 | -1,209 | -1,102 | -1,000 | -960 | -906 | -881 | -901 | -772 | -739 | -702 | -679 | -649 | -620 | -587 |
Additional Paid-In Capital | 0.2% | 1,737 | 1,734 | 1,728 | 1,711 | 1,701 | 1,694 | 1,642 | 1,610 | 1,557 | 1,551 | 1,542 | 1,367 | 1,206 | 1,088 | 958 | 743 | 735 | 732 | 727 | 708 | 691 |
Shares Outstanding | -100.0% | - | 264 | 258 | 253 | 249 | 235 | 219 | 217 | 210 | 210 | 202 | 187 | 165 | 156 | 125 | 101 | 99.00 | 98.00 | 97.00 | 93.00 | 92.00 |
Minority Interest | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 | 4.00 | 2.00 | 2.00 | 3.00 | 3.00 | 0.00 | 0.00 |
Cashflow (Quarterly) | (In Thousands) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Cashflow From Operations | 9.9% | -29,110 | -32,314 | -36,664 | -36,340 | -67,465 | -50,527 | -61,882 | -37,891 | -46,490 | -78,459 | -52,867 | -51,216 | -74,158 | -27,151 | -25,452 | -13,737 | -27,733 | -23,924 | -32,454 | -17,281 | -24,670 |
Share Based Compensation | -28.7% | 2,079 | 2,918 | 3,809 | 3,274 | 3,234 | 8,336 | 7,711 | 5,474 | 5,620 | 5,646 | 9,596 | 3,825 | 4,158 | 3,662 | 4,002 | 2,034 | 2,080 | 3,355 | 3,433 | 2,138 | 2,351 |
Cashflow From Investing | -110.2% | -5,493 | 53,907 | 19,000 | 54,001 | 44,557 | -10,304 | 21,332 | -6,493 | 55,958 | 50,306 | -275,115 | -3,716 | 39,115 | -42,385 | -51,808 | 10,435 | 8,270 | 21,588 | -49,337 | 7,183 | 14,418 |
Cashflow From Financing | -75.8% | 699 | 2,883 | -424 | 6,668 | 3,812 | 42,939 | 28,422 | 47,595 | -440 | 3,441 | 160,903 | 126,939 | -1,695 | 126,523 | 213,513 | 9,645 | 15,581 | 1,294 | 78,877 | 14,394 | 14,565 |
Condensed Consolidated Statements of Operations - USD ($) | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Revenues: | ||||
Revenue from collaborative arrangements and other contracts | $ 388,446 | $ 9,154,133 | $ 729,359 | $ 10,137,602 |
Operating expenses: | ||||
Research and development | 15,503,032 | 33,087,130 | 69,423,513 | 145,530,626 |
General and administrative | 9,925,055 | 11,824,047 | 37,338,763 | 76,234,341 |
Impairment of goodwill | 10,513,371 | 0 | 10,513,371 | 0 |
Total operating expenses | 35,941,458 | 44,911,177 | 117,275,647 | 221,764,967 |
Loss from operations | (35,553,012) | (35,757,044) | (116,546,288) | (211,627,365) |
Other income (expense): | ||||
Interest income | 1,938,745 | 1,365,759 | 6,314,149 | 2,893,240 |
Interest expense | (313,488) | (313,488) | (940,464) | (940,464) |
Gain (loss) on investment in affiliated entity | 214,374 | (305,061) | 987,758 | (1,776,804) |
Net unrealized gain (loss) on available-for-sale equity securities | (219,337) | (1,833,284) | 3,921,819 | (10,641,026) |
Other income (expense), net | 2,854 | (940,778) | (3,850,688) | (1,097,294) |
Net loss before share in net loss of Geneos | (33,929,864) | (37,783,896) | (110,113,714) | (223,189,713) |
Share in net loss of Geneos | 0 | 0 | 0 | (2,165,213) |
Net loss | $ (33,929,864) | $ (37,783,896) | $ (110,113,714) | $ (225,354,926) |
Net loss per share | ||||
Basic (in dollars per share) | $ (0.13) | $ (0.15) | $ (0.42) | $ (0.96) |
Diluted (in dollars per share) | $ (0.13) | $ (0.15) | $ (0.42) | $ (0.96) |
Weighted average number of common shares outstanding | ||||
Basic (in shares) | 268,622,753 | 249,351,023 | 263,842,074 | 234,634,724 |
Diluted (in shares) | 268,622,753 | 249,351,023 | 263,842,074 | 234,634,724 |
Condensed Consolidated Balance Sheets - USD ($) | Sep. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 18,804,602 | $ 46,329,359 |
Short-term investments | 148,668,866 | 206,669,397 |
Prepaid expenses and other current assets | 5,114,873 | 50,130,481 |
Prepaid expenses and other current assets from affiliated entities | 34,923 | 375,227 |
Total current assets | 174,767,197 | 315,242,680 |
Fixed assets, net | 5,632,511 | 7,727,997 |
Investment in affiliated entity | 2,994,900 | 2,007,142 |
Intangible assets, net | 0 | 2,129,861 |
Goodwill | 0 | 10,513,371 |
Operating lease right-of-use assets | 9,097,275 | 10,228,207 |
Other assets | 605,315 | 684,044 |
Total assets | 193,097,198 | 348,533,302 |
Current liabilities: | ||
Accrued clinical trial expenses | 5,011,185 | 10,594,073 |
Operating lease liability | 2,117,971 | 2,803,973 |
Grant funding liability | 3,806,161 | 2,475,031 |
Grant funding liability from affiliated entity | 21,918 | 87,673 |
Convertible senior notes | 16,488,329 | 0 |
Total current liabilities | 43,711,026 | 96,868,074 |
Convertible senior notes | 0 | 16,614,840 |
Operating lease liability, net of current portion | 11,194,413 | 12,655,586 |
Deferred tax liabilities | 32,046 | 32,046 |
Total liabilities | 54,937,485 | 126,170,546 |
Stockholders’ equity: | ||
Preferred stock | 0 | 0 |
Common stock | 269,730 | 253,090 |
Additional paid-in capital | 1,736,602,555 | 1,710,656,191 |
Accumulated deficit | (1,597,961,498) | (1,487,847,784) |
Accumulated other comprehensive loss | (751,074) | (698,741) |
Total Inovio Pharmaceuticals, Inc. stockholders’ equity | 138,159,713 | 222,362,756 |
Total liabilities and stockholders’ equity | 193,097,198 | 348,533,302 |
Nonrelated Party | ||
Current assets: | ||
Accounts receivable | 0 | 1,701,726 |
Current liabilities: | ||
Accounts payable and accrued expenses | 15,553,742 | 79,686,885 |
Related Party | ||
Current assets: | ||
Accounts receivable | 2,143,933 | 10,036,490 |
Current liabilities: | ||
Accounts payable and accrued expenses | $ 711,720 | $ 1,220,439 |
 CEO | Dr. Jacqueline E. Shea Ph.D. |
---|---|
 WEBSITE | www.inovio.com |
 EMPLOYEES | 135 |